Type 2 Diabetes Prevention and Therapy. Veronica Piziak MD, PhD Scott and White
|
|
- Alfred Evans
- 8 years ago
- Views:
Transcription
1
2
3 Type 2 Diabetes Prevention and Therapy Veronica Piziak MD, PhD Scott and White
4 Disclosures: Research support: J&J Objectives: Epidemiology of diabetes Diagnosis of diabetes Treatment goals
5 Every Day in the United States Approximately 66 people lose their eyesight because of diabetes 128 people begin treatment for end-stage renal disease (ESRD) More than 4000 new cases* of diabetes will be diagnosed today 195 lower-limb amputations are performed because of diabetes 640 people die from diabetes and its complications *Patients ages 20 years. Centers for Disease Control. National Diabetes Fact Sheet. Accessed March 5, 2009.
6 Type 2 Diabetes Associated with Serious Complications Diabetic Retinopathy Leading cause of blindness in adults Stroke CV Disease & Stroke account for ~85% of deaths in T2D patients Cardiovascular Disease Diabetic Nephropathy Major cause of kidney failure Diabetic Neuropathy Major cause of lower extremity amputations CV = cardiovascular. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, Bethesda, MD: U.S. Department of Health and Human Services, National Institute of Health, 2005.
7 Type 2 Diabetes Definition A disorder of glucose, lipid, protein metabolism characterized by peripheral insulin resistance, inadequate pancreatic insulin secretory response and disordered glucagon supression. Risk factors: Obesity Heredity Environment
8 Obesity Trends Among U.S. Adults 2010 (*BMI 30, or ~ 30 lbs. overweight for 5 4 person) No Data <10% 10% 14% 15% 19% 20% 24% 25% 29% 30% CDC Data 2010
9 State-specific Prevalence of Obesity* Among U.S. Adults, by Race/Ethnicity, White non-hispanic Black non- Hispanic Hispani c (*BMI 30)
10 High fructose corn syrup GLUCOSE HYPERTRIGLYCERIDEMIA HEART DISEASE
11 Can Diabetes be Prevented? Yes Diet High fiber, low sugar, low fat 5% weight loss 150 minutes of exercise / week
12 When to use Metformin for prevention In addition to lifestyle counseling, metformin may be considered in those who are at very high risk for developing diabetes (combined IFG and IGT plus other risk factors such as A1C >6% Pre diabetes Hypertension, low HDL cholesterol, elevated triglycerides, or family history of diabetes in a first-degree relative) and who are obese and under 60 Metabolic syndrome ADA practice guidelines 2011
13 Diagnosis of Diabetes A1c may now be used Prediabetes % Diabetes 6.5% Laboratory determination, venous sample Not point of care testing ADA practice guidelines 2011
14 Fasting Glucose (mmol/l) Diagnostic Criteria for Diabetes, IFG, and IGT (mg/dl) IFG Normal glucose IFG + IGT IGT h Postload Glucose (mmol/l) IFG = impaired fasting glucose. American Diabetes Association. Diabetes Care. 2003;26(suppl 1):S5-S20. Diabetes (mg/dl)
15 ADA Treatment Goals Hyperglycemia Hypertension Dyslipidemia FPG/ 90 PPG A1C Blood pressure LDL HDL Triglycerides American Diabetes Association. Diabetes Care mg/dl <180 mg/dl < 7% lowest possible without hypoglycemia < 130/<80 lower if renal disease <100 mg/dl, patients with diabetes (70( 70-90) <70 mg/dl, very high risk patients with diabetes and CVD >50 mg/dl, women >40 men < 150mg/dl
16 ADA RENAL GUIDELINES MICROALBUMIN/CREATININE SPOT URINE ANNUAL SCREENING ANNUAL CREATININE ESTIMATE GFR TO CHECK FOR DISEASE calculator.cfm NEED AGE,GENDER,CREATININE,RACE
17 ADA RENAL GUIDELINES ESTIMATE GFR ANUALLY STAGE ML/MIN 1.RENAL DAMAGE NORMAL OR INCREASED GFR =/>90 2.RENAL DAMAGE MILDLY DECREASED GFR MODERATELY DECREASED GFR SEVERELY DECREASED GFR RENAL FAILURE <15 DIALYSIS STAGE 3 OR MORE REFER Diabetes Care 2011; 29:S
18 STATIN IN DIABETES CONTROL OF: LIPIDS LDL < 100 (<70) > Age 40 Statins recommended regardless of LDL Reduce the LDL by 30-40% ADA Practice Guidelines Jan 2011 Diabetes Care Statins are contraindicated in pregnancy Aspirin in any diabetic who has had a CV event and men> 50, women >60 with a risk factor
19 The Goals of Glucose Control Depend on the patient and the duration of disease
20 How Low should we go? Early aggressive therapy <7.0 if possible without hypoglycemia ADA Guidelines Goals of therapy: Control glucose individual level for patient HbA1c 7-7.5% 7 7.5% for patients with multiple comorbidities?? Avoid hypoglycemia! Prevent microvascular complications Prevent macrovascular complications Montori VM, Fernandez-Balsells ann Int Med 2009;150:
21 How low should you go? Community based study of patients between age with Type 2 diabetes A1c and death >10 highest death rate > 8 to < 6 next highest death rate Lowest death rate between 6 8 < 7 goal is from UKPDS Excluded patients age >60 Newly diagnosed diabetes Huang et al Diabetes Care June 2011
22 INVEST Blood pressure control Diabetic patients with SBP not controlled (>( 140 mm Hg) had the worst outcomes. Tight Control < 130 mm Hg) of SBP was not associated with improved CV outcomes compared with Usual Control ( mm Hg) There was increased risk for mortality in the Tight Control group which persisted during extended follow-up SBP < 115 mm Hg was associated with an increase in risk for mortality
23 INVEST Results: Outcomes Tight Control Group All Cause Mortality (n=2255) Adjusted Hazard Ratios Reference 0.5 <110 Other Significant Variables in Cox Regression Model < < < <130 Systolic Blood Pressure (mmhg) Age, Race, PAD, MI, CHF, US Residency, Renal Impairment, LVH, TIA/Stroke Cooper-Dehoff R. ACC Late-Breaking Clinical Trials. Atlanta, GA
24 Intensive vs Conventional Glucose Control in Critically Ill Patients The NICE-SUGAR Investigators 3000 patients completed in each arm, groups well matched Methods Within 24 hours after admission to an intensive care unit (ICU), adults were randomly assigned to undergo either intensive glucose control, target blood glucose range of 81 to 108 mg% conventional glucose control, with a target of 180 mg% or less The primary end point as death from any cause within 90 days after randomization NEJM;360:1283
25 Results: A total of 829 patients (27.5%) in the intensive-control group and 751 (24.9%) in the conventional-control control group died (odds ratio for intensive control, 1.14, 95% confidence interval, 1.02 to 1.28; P=0.02). Operative (surgical) patients and nonoperative (medical) patients (odds ratio for death in the intensive-control group, 1.31 and 1.07, respectively; P=0.10). NS Severe hypoglycemia (blood glucose level, 40 mg per deciliter was reported in 206 of 3016 patients (6.8%) in the intensive-control group and 15 of 3014 (0.5%) in the conventional-control control group (P<0.001). There was no significant difference between the two treatment groups in the median number of days in the ICU (P=0.84) or hospital (P=0.86) or the median number of days of mechanical ventilation (P=0.56) or renal-replacement replacement therapy (P=0.39). Conclusion: Blood glucose target of less than 180 mg% resulted in lower mortality than a target of 81 to 108 mg%. On the basis of our results, we do not recommend use of the lower target in critically ill adults. Check Mayo Clinic Proceedings May 2009;84:400 Question 40, 89 NICE-SUGAR Study
26 Diabetes Education The basis for adequate diabetes control
27 New 2009 AACE/ACE Algorithm Lifestyle Modification A1c %* A1c % A1c > 9.0% MET TZD DPP 2 AGI MET + TZD MET Monotherapy 2 3 months Dual Therapy + MET + GLP-1 + or DPP4 1 GLP-1 or DPP4 1 TZD 2 Glinide or SU 5 GLP-1 or DPP4 1 + Colesevelam 2 3 AGI 3 months Triple Therapy TZD 2 INSULIN ± Other Agent(s) 6 Glinide or SU 4,7 2 3 months MET + MET + Dual Therapy 8 GLP-1 or DPP4 1,10 or TZD 2 SU or Glinide 4,5 Triple Therapy 9 GLP-1 or DPP4 1 GLP-1 or DPP4 1 TZD 2 INSULIN ± Other Agent(s) months +TZ D 2 +SU months Symptoms INSULIN ± Other Agent(s) 6 Drug Naive No Symptoms MET + Under Treatment GLP-1 or DPP4 1 ±SU 7 TZD 2 GLP-1 ±TZD or D DPP4 1 2 INSULIN ± Other Agent(s) 6 Rodbard HW, et al. Endocrine Practice. 2009;15(6):
28 Treating Diabetes: Insulin resistance Beta and Alpha Cell Dysfunction
29 Antidiabetic agents: Mechanism of Action 4 Liver: hepatic glucose output Metformin HGO 1 Intestine: glucose/fat absorption decreased digestion of carbohydrate/fat Acarbose/ bile acid binding resin bromocriptine Insulin resistance Blood glucose 2 Muscle and adipose tissue: glucose uptake/ glucose utilization Metformin, TZDs TZD s careful preserve Beta cell function #43 decrease dose with insulin Insulin resistance 3 Pancreas: insulin secretion Sulfonylureas, nateglinide DeFronzo RA. Diabetes. 1988;37: Lebovitz HE. In Joslin's Diabetes Mellitus. 1994: ; Amatruda JM. In: Diabetes Mellitus DeFronzo RA et al. J Clin Endocrinol Metab. 1991;73: Whitcomb RW et al. In: Diabetes Mellitus. 1996;Cavaghan MK et al. J Clin Invest. 1997;100: Ehrmann DA et al. J Clin Endocrinol Metab. 1997;82: ; Wolffenbuttel BHR. Eur J Clin Pharmacol. 1993;45:
30 GLP-1 1 Modes of Action in Humans Upon ingestion of food Stimulates glucose-dependent insulin secretion Suppress glucagon secretion Slows gastric emptying GLP-1 is secreted from the L-cells in the intestine This in turn Reduces food intake Improves insulin sensitivity Long term effects demonstrated in animals Increases beta-cell mass and maintains beta-cell efficiency Drucker DJ. Curr Pharm Des 2001; 7: Drucker DJ. Mol Endocrinol 2003; 17:
31 Improvement in Cardiovascular Risk Factors with 3.5 Years of Exenatide Treatment (n = 151) Change from Baseline LDL-C C (mg/dl) ± Systolic Blood Pressure (mmhg) -3.5 ± 1.2-2% Diastolic Blood Pressure (mmhg) -3.3 ± 0.8-4% HDL-C C (mg/dl) 8.5 ± % Triglycerides (mg/dl) ± % Total Cholesterol (mg/dl) ± 3.1-5% Weight loss avg 5.3 kg Klonoff DC, et al. Curr Med Res Opin 2008;24: Nausea main side effect (use 20 minutes before meals), pancreatitis possible. Do not use Cr Cl <30 Caution CrCl <50
32 Liraglutide (Victoza) 0.6 mg / day starting dose Titrate mg / day Multidose pens Reduces postmeal glucose (A1c 1% lower) Nausea most common side effect Associated with pancreatitis in rare instances Use with metformin, sulfonylureas, TZD Weight loss 2 kg/26 weeks Medullary carcinoma in animals
33 GLP-1 1 Secretion and Inactivation meal Intestinal GLP-1 release T 1/2 = 1 to 2 min Active GLP-1 DPP-4 GLP-1 inactive (>80% of pool) DPP-4 = dipeptidyl peptidase 4; GLP-1 = glucagon-like peptide 1. Deacon CF, et al. Diabetes. 1995;44:
34 Mean Change in FPG, mg/dl Sitagliptin Monotherapy (Januvia) Significantly Lowers FPG and PPG Levels 24-week placebo-adjusted results FPG Mean Baseline: 170 mg/dl P<0.001* n = 234 (95% CI: 24, 10) Mean Change in 2-Hour PPG, mg/dl Hour PPG Mean Baseline: 257 mg/dl P<0.001* (95% CI: 59, 34) n = 201 *Compared with placebo. Least-squares means adjusted for prior antihyperglycemic therapy status and baseline value. Difference from placebo. CI=confidence interval; FPG=fasting plasma glucose; PPG=postprandial plasma glucose (meal challenge test). Aschner P et al. Diabetes Care. 2006;29:
35 Sitagliptin: Once-Daily Dosing Proven 24-Hour Glycemic Control Patients With Renal Insufficiency*, A dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with end-stage renal disease requiring hemodialysis or peritoneal dialysis. 50 mg once daily 25 mg once daily Moderate CrCl 30 to <50 ml/min (~Serum Cr levels [mg/dl] Men: > ; Women: > ) Severe and ESRD CrCl <30 ml/min (~Serum Cr levels [mg/dl] Men: >3.0; Women: >2.5) Assessment of renal function is recommended prior to initiation and periodically thereafter. * can be taken with or without food. Patients with mild renal insufficiency 100 mg once daily. ESRD=end-stage renal disease requiring hemodialysis or peritoneal dialysis. Answer to question #50
36 Saxagliptin (Onglyza) 2.5, 5 mg Lowers A1c about 0.5-1% May be used with dose adjustment in renal insufficiency No weight loss
37 Linaglipitin (Tradjenta) Approved for type 2 diabetes DPP-4 4 inhibitor Monotherapy, combination with Metformin,Sulfonylurea, pioglitazone A1c decreased 0.7% Only 1 dose 5mg/day
38 Bile Acid Binding Resin Colesevelam (Welchol) Approved for use in Type 2 diabetes Lowers A1c by 0.8% 625 mg x 6/day Add on to metformin May increase triglycerides when used with sulfonylurea or insulin. Don t t use when triglycerides are >500 May have GI side effects May cause malabsorption of medications
39 Cycloset - bromocriptine Quick-release formulation of bromocriptine that increases CNS dopaminergic activity. Lowers the A1c by about 0.8 % Weigh neutral, no hypoglycemia Nausea is the major side effect Initial dose is one 0.8 mg tablet daily, titrated weekly by 1 tablet until therapeutic dose (1.6 to 4.8 mg, or between 2 and 6 tablets per day) is achieved.
40 Plasma Insulin Levels Action Profiles of Insulins Aspart, glulisine, lispro 4 5 hours Regular 6 8 hours NPH hours More nocturnal hypoglycemia #73 Detemir ~14 hours Glargine ~24 hours Hours Burge MR, Schade DS. Endocrinol Metab Clin North Am. 1997;26: ; Barlocco D. Curr Opin Invest Drugs. 2003;4: ; Danne T et al. Diabetes Care. 2003;26:
41 What does basal insulin cover? Excessive gluconeogenesis Does this occur in the hospital? Does stress occur in the hospital? Protein and fat intake to some extent Calculate the starting dose: Type 2: units / kg/day Teach the patient to titrate
42 Action Profiles of short acting Insulins Aspart, glulisine, lispro 4 5 hours Regular 6 8 hours Plasma Insulin Levels Hours Burge MR, Schade DS. Endocrinol Metab Clin North Am. 1997;26: ; Barlocco D. Curr Opin Invest Drugs. 2003;4: ; Danne T et al. Diabetes Care. 2003;26:
43 RATE AT WHICH NUTRIENTS CHANGE BLOOD GLUCOSE % C H A N G E Carbohydrate Protein FAT Rate of Change in hours
44 Bolus insulin Meal supplement Mainly covers carbohydrate Helps with protein and fat coverage Correction factor Compensates for insufficient basal insulin or insufficient meal supplement If NPO use regular insulin q 6 hours
45 BOLUS COVERAGE Correction factor Supplemental scale May use anytime Meal times are convenient x units/ y mg%> z mg% Insulin resistance Type units/50 mg%>150 mg%
46 BOLUS INSULINGO FIGURE: Type 2 Diabetes Meal coverage Counting carbohydrates 1 unit / 5-10 gm CHO Can t count carbs? MD count them and estimate the meal supplement
47 Summary Type 2 is increasing at a rate that parallels obesity Prevention is vitally important Consider A1c for diagnosis Treatment goals vary with the duration and of the disease
Up to Date for Diabetes: Veronica Piziak MD, PhD Professor of Medicine Texas A&M Emeritus Director of Endocrinology Baylor Scott and White
Up to Date for Diabetes: Veronica Piziak MD, PhD Professor of Medicine Texas A&M Emeritus Director of Endocrinology Baylor Scott and White Objectives: What is New in Therapy How to select medications Disclosures:
More informationDistinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationGlucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationUpdate on the management of Type 2 Diabetes
Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationVolume 01, No. 08 November 2013
State of New Jersey Department of Human Services Division of Medical Assistance & Health Services New Jersey Drug Utilization Review Board Volume 01, No. 08 November 2013 TO: SUBJECT: PURPOSE: Physicians,
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationMary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationLong term Weight Management in Obese Diabetic Patients Osama Hamdy, MD, PhD, FACE
Long term Weight Management in Obese Diabetic Patients Osama Hamdy, MD, PhD, FACE Medical Director, Obesity Clinical Program, Director of Inpatient Diabetes Management, Joslin Diabetes Center Assistant
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationNutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
More informationTreatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.
National Diabetes Statistics What is diabetes? Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationType II diabetes: How to use the new oral medications
Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationAdd: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above
Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random
More informationDiabetes Fundamentals
Diabetes Fundamentals Prevalence of Diabetes in the U.S. Undiagnosed 10.7% of all people 20+ 23.1% of all people 60+ (12.2 million) Slide provided by Roche Diagnostics Sources: ADA, WHO statistics Prevalence
More informationDefinition of Diabetes Mellitus
Definition of Diabetes Mellitus Diabetes mellitus consists of a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both. U.S. Diabetes
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationDiabetes Mellitus Type 2
Diabetes Mellitus Type 2 What is it? Diabetes is a common health problem in the U.S. and the world. In diabetes, the body does not use the food it digests well. It is hard for the body to use carbohydrates
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationPrimary Care Type 2 Diabetes Update
Primary Care Type 2 Diabetes Update May 16, 2014 Presented by: Barb Risnes APRN, BC-ADM, CDE Objectives: Discuss strategies to address common type 2 diabetes patient management challenges Review new pharmacological
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationHow To Treat Diabetes
Overview of Diabetes Medications Marie Frazzitta DNP, FNP c, CDE, MBA Senior Director of Disease Management North Shore LIJ Health Systems Normal Glucose Metabolism Insulin is produced by beta cells in
More informationPowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.
PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY 12a FOCUS ON Your Risk for Diabetes Your Risk for Diabetes! Since 1980,Diabetes has increased by 50 %. Diabetes has increased by 70 percent
More informationDR. Trinh Thi Kim Hue
TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationAbdulaziz Al-Subaie. Anfal Al-Shalwi
Abdulaziz Al-Subaie Anfal Al-Shalwi Introduction what is diabetes mellitus? A chronic metabolic disorder characterized by high blood glucose level caused by insulin deficiency and sometimes accompanied
More informationDisclosures. Types of Diabetes Mellitus. Type 1 Diabetes Mellitus. Principles of Basal-Bolus Insulin Therapy and Carbohydrate Counting
Principles of Basal-Bolus Insulin Therapy and Carbohydrate Counting Disclosures I do not have any relevant financial relationships with any commercial interests. Henry K. Driscoll, MD, FACP Huntington
More informationDr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy
Dr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationTreating Type 2 Diabetes Mellitus: a New York State Medicaid Clinical Guidance Document
Treating Type 2 Diabetes Mellitus: a New York State Medicaid Clinical Guidance Document Disclaimer: This document is offered as a service to New York State Prescribers to inform about the most current
More informationPharmaceutical Management of Diabetes Mellitus
1 Pharmaceutical Management of Diabetes Mellitus Diabetes Mellitus (cont d) Signs and symptoms 2 Elevated fasting blood glucose (higher than 126 mg/dl) or a hemoglobin A1C (A1C) level greater than or equal
More informationChallenges in Glycemic Control in Adult and Geriatric Patients. Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner
Challenges in Glycemic Control in Adult and Geriatric Patients Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner Provide an overview of diabetes prevalence; discuss challenges and barriers
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationType 2 Diabetes Medicines: What You Need to Know
Type 2 Diabetes Medicines: What You Need to Know Managing diabetes is complex because many hormones and body processes are at work controlling blood sugar (glucose). Medicines for diabetes include oral
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationDiabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO
Diabetes and Obesity in Children Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children What is Diabetes? How are Diabetes and Obesity
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationAntidiabetic Drugs. Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Antidiabetic Drugs Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Diabetes Mellitus Two types Type 1 Type 2 Type 1 Diabetes Mellitus Lack of insulin production
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationPrevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes
More informationType 2 diabetes Definition
Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes
More informationType 2 Diabetes. Jonathon M. Firnhaber, MD. Assistant Professor, Residency Program Director East Carolina University Greenville, North Carolina
Type 2 Diabetes Jonathon M. Firnhaber, MD Assistant Professor, Residency Program Director East Carolina University Greenville, North Carolina Verbal Disclosure It is the policy of the AAFP that all individuals
More informationManaging Patients Newly Diagnosed with Diabetes. Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON
Managing Patients Newly Diagnosed with Diabetes Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON 1 Conflict Disclosure Information Conflict Disclosure Information
More informationManagement of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationDIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS
Section Two DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS This section will: Describe oral agents (pills) are specific for treating type 2 diabetes. Describe other hypoglycemic agents used
More informationDiabetes DIABETES MELLITUS. Types of Diabetes. Classification of Diabetes 6. 10. 2013. Prediabetes: IFG, IGT, Increased A1C
Diabetes Diabetes mellitus is a chronic disease characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. A state of raised blood glucose (hyperglycaemia)
More informationAACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM
AACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013 TASK FORCE Alan J. Garber, MD, PhD, FACE, Chair Martin J. Abrahamson, MD Joshua I. Barzilay, MD, FACE Lawrence Blonde, MD, FACP, FACE Zachary T. Bloomgarden,
More informationNoninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause hypoglycemia MED GROUP DESCRIPTOR
Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause MED GROUP DESCRIPTOR INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) MICRONIZED GLYBURIDE*
More informationETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes
DIABETES MELLITUS DEFINITION It is a common, chronic, metabolic syndrome characterized by hyperglycemia as a cardinal biochemical feature. Resulting from absolute lack of insulin. Abnormal metabolism of
More informationCauses, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
More informationAntihyperglycemic Agents Comparison Chart
Parameter Metformin Sulfonylureas Meglitinides Glitazones (TZD s) Mechanism of Action Efficacy (A1c Reduction) Hepatic glucose output Peripheral glucose uptake by enhancing insulin action insulin secretion
More informationSecond- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More informationWelchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationFundamentals of Diabetes Care Module 5, Lesson 1
Module 5, Lesson 1 Fundamentals of Diabetes Care Module 5: Taking Medications Healthy Eating Being Active Monitoring Taking Medication Problem Solving Healthy Coping Reducing Risks Foundations For Control
More informationManagement of Type 2 Diabetes Mellitus in the Elderly
Management of Type 2 Diabetes Mellitus in the Elderly ANDREA FERENCZI, M.D. BANNER ARIZONA MEDICAL CLINIC DEPARTMENT OF ENDOCRINOLOGY Incidence and Prevalence of Diabetes in the United States County-level
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationDIABETES MELLITUS GUIDELINES
DIABETES MELLITUS GUIDELINES Virginia Premier Health Plan Virginia Premier Health Plan, Clinical Practice Guideline-Diabetes 1. Population screening a. Indications i. Adults of any age with body mass index
More informationTargeting the Kidney. Renal Glucose Transport 11/4/2015. Non insulin Agents Available IBITORS. Chao EC, et al. Nat Rev Drug Discovery. 2010;9:551 559.
SGLT-2i and DPP-IVi in the Management of Diabetes Mellitus Type 2 Abel Alfonso, D.O., F.A.C.E. Endocrinologist November 5, 2015 DIABETES: CURRENT RATES AND PROJECTIONS CDC Press Release 2010: 1 in 3 adults
More informationDiabetes, Type 2. RelayClinical Patient Education Sample Topic Diabetes, Type 2. What is type 2 diabetes? How does it occur?
What is type 2 diabetes? Type 2 diabetes is a disorder that happens when your body does not make enough insulin or is unable to use its own insulin properly. The inability to use insulin is called insulin
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
More informationDiabetes is a. A case for prevention of type 2 diabetes mellitus
A case for prevention of type 2 diabetes mellitus Joseph Cook, DO Diabetes is a disease that has reached epidemic proportions in the United States and around the world. This is troubling because, as bad
More informationDiabetes Medications. Minal Patel, PharmD, BCPS
Diabetes Medications Minal Patel, PharmD, BCPS Objectives Examine advantages and disadvantages of oral anti-hyperglycemic medications Describe the differences between different classes of insulin Explore
More informationDiabetes 101: A Brief Overview of Diabetes and the American Diabetes Association What Happens When We Eat?
Diabetes 101: A Brief Overview of Diabetes and the American Diabetes Association What Happens When We Eat? After eating, most food is turned into glucose, the body s main source of energy. 1 Normal Blood
More informationNewer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013
Newer Anticoagulants and Newer Diabetic Drug Classes Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Apixaban Newer Anticoagulants Dabigatran etexilate Rivaroxaban
More informationAACE/ACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been accepted for publication in an issue of Endocrine Practice. This version
More informationTHE PATHOPHYSIOLOGIC BASIS FOR DIABETES TREATMENT: EVALUATING THE EFFECT OF INCRETIN-BASED THERAPIES * Jack Leahy, MD
THE PATHOPHYSIOLOGIC BASIS FOR DIABETES TREATMENT: EVALUATING THE EFFECT OF INCRETIN-BASED THERAPIES * Jack Leahy, MD ABSTRACT Type 2 diabetes is a persistent public health challenge that requires innovative
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationDM Management in Elderly- What are the glucose targets?
DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011 Disclosures
More informationAdult Diabetes Clinician Guide
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction JANUARY 2016 This evidence-based guideline summary is based on the 2016 National Diabetes Guideline.
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More informationType 2 diabetes is a progressive. status
Type 2 diabetes is a progressive disease: its treatment the current status Associate Professor Jonathan Shaw Why is type 2 diabetes so hard to treat? How to choose the right glucose-lowering g drug? Page
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationComparative Review of Oral Hypoglycemic Agents in Adults
SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms:... 3 I. Background and Rationale for the review:... 4 II. Medications
More informationDCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More information